Surrender to multinationals
India is about to lose on the home front what it had won in Geneva--its Patent Ordinance gives pharmaceutical multinationals what the United States had failed to win for them at the negotiating table. Read full article This article is reproduced here with the author’s consent. It is also featured in the February 23rd edition of The Economic Times. Representing the interests of its ultra-powerful pharmaceutical multinationals, the United States had pushed for a very high level of patent protection for medicines during the Uruguay Round negotiations. India, which had witnessed its poor benefit greatly from the low-cost generic-drugs industry that grew around its relatively weak patent regime for medicines, had led the fight against this U.S. push. In the end, though the United State was largely successful in achieving its objectives, India managed to push a set of flexibilities into the Uruguay Round Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS) that could be used to protect the interests of the consumers against those of the multinationals. It now appears, however, that India too has capitulated to…
Continue reading...